Ryzodeg® (insulin degludec/insulin aspart) approved in Japan

Bagsværd, Denmark, 25 December 2012 - Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Ryzodeg^® (insulin degludec/insulin aspart) for the treatment of diabetes.

Further information

Media:
Mike Rulis	+45 4442 3573	mike@novonordisk.com
Ambre Morley (US)	+1 609 216 5240	abmo@novonordisk.com
Investors:
Kasper Roseeuw Poulsen	+45 4442 4303	krop@novonordisk.com
Frank Daniel Mersebach	+45 4442 0604	fdni@novonordisk.com
Lars Borup Jacobsen	+45 3075 3479	lbpj@novonordisk.com
Jannick Lindegaard (US)	+1 609 786 4575	jlis@novonordisk.com

Company announcement No 84 /2012